Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

February 2022

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 FEBRUARY 2022

- Baricitinib (Olumiant) tab 2 mg and 4 mg – new listing
- Betahistine dihydrochloride (Serc) tab 16 mg – new listing and transfer of HSS
- Betahistine dihydrochloride (Vergo 16) tab 16 mg – removal of HSS and to be delisted 1 July 2022
- Bortezomib inj 2.5 mg vial – presentation to be delisted 1 August 2022
- Calcium lactate gluconate with calcium carbonate (e.g. Calcium-Sandoz Forte) tab eff 2.94 g with calcium carbonate 0.3 g (500 mg elemental) – chemical name change
- Casirivimab and imdevimab (Ronapreve) inj 120 mg per ml casirivimab, 11.1 ml vial (1) and inj 120 mg per ml imdevimab, 11.1 ml vial (1), 1 treatment pack – new listing
- Clonidine hydrochloride (Clonidine Teva) tab 25 mcg – new listing
- Megestrol acetate (Megace) tab 160 mg – new listing and to be delisted 1 February 2023
- Mivacurium chloride (Mivacron) inj 2 mg per ml, 5 ml ampoule – brand to be delisted 1 August 2022
- Mivacurium chloride (Mivacron) inj 2 mg per ml, 10 ml ampoule – brand delisted 1 February 2022
- Oxycodone hydrochloride (Hameln) inj 10 mg per ml, 1 ml and 2 ml ampoule and inj 50 mg per ml, 1 ml ampoule – new listing and addition of PSS
- Oxycodone hydrochloride (Oxynorm) inj 10 mg per ml, 1 ml and 2 ml ampoule and inj 50 mg per ml, 1 ml ampoule – to be delisted 1 July 2022
- Oxazepam (Ox-Pam) tab 10 mg and 15 mg – brand to be delisted 1 April 2022
- Nicotine oral spray 1 mg per dose (e.g. Nicorette QuickMist Mouth Spray) and soln for inhalation 15 mg cartridge (e.g. Nicorette Inhalator) – amended restriction criteria
- Paediatric oral feed 1 kcal/ml (Pediasure (chocolate), Pediasure (Strawberry) and Pediasure (Vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bottle – presentation description change
- Paediatric oral feed 1 kcal/ml (Pediasure (Vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, can – presentation description change
- Paediatric oral feed 1.5 kcal/ml (e.g. Pediasure Plus) liquid 4.2 g, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle – new listing
- Sunitinib (Sunitinib Pfizer) cap 12.5 mg, 25 mg and 50 mg – new listing and addition of PSS
- Sunitinib (Sutent) cap 12.5 mg, 25 mg and 50 mg – to be delisted 1 July 2022

Summary of decisions – effective 1 February 2022 (continued)

- Tocilizumab (Actemra) inj 20 mg per ml, 4 ml vial, 10 ml vial and 20 ml vial – amended restriction criteria

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 February 2022

ALIMENTARY TRACT AND METABOLISM

20 CALCIUM **LACTATE** GLUCONATE WITH CALCIUM CARBONATE (chemical name change)
Tab eff 2.94 g with calcium carbonate 0.3 g (500 mg elemental) *e.g. Calcium-Sandoz Forte*

CARDIOVASCULAR SYSTEM

47 CLONIDINE HYDROCHLORIDE (new listing)

Tab 25 mcg	36.50	112	Clonidine Teva

MUSCULOSKELETAL SYSTEM

106 MIVACURIUM CHLORIDE (brand delisting)

Inj 2 mg per ml, 5 ml ampoule	33.92	5	Mivacron
Inj 2 mg per ml, 10 ml ampoule	67.17	5	Mivacron

Note – Mivacron inj 2 mg per ml, 5 ml ampoule to be delisted on 1 August 2022 and 10 ml ampoule delisted 1 February 2022 (brand only).

NERVOUS SYSTEM

109 BROMOCRIPTINE (delist delayed)
➔ Tab 2.5 mg – Restricted: For continuation only
Note – this delist delayed from 1 March 2022 to 1 September 2022.

116 OXYCODONE HYDROCHLORIDE (brand change and addition of PSS)

Inj 10 mg per ml, 1 ml ampoule – **5% DV Jul-22 to 2024**	5.82	5	**Hameln**
Inj 10 mg per ml, 2 ml ampoule – **5% DV Jul-22 to 2024**	11.49	5	**Hameln**
Inj 50 mg per ml, 1 ml ampoule – **5% DV Jul-22 to 2024**	22.92	5	**Hameln**

Note – OxyNorm inj 10 mg per ml, 1 ml ampoule, 2 ml ampoule and inj 50 mg per ml, 1 ml ampoule to be delisted 1 July 2022.

122 BETAHISTINE DIHYDROCHLORIDE (brand change and transfer of HSS)

Tab 16 mg – **1% DV Feb-22 to 2023**	4.62	100	**Serc**

Note – Vergo 16 tab 16 mg to be delisted 1 July 2022.

127 OXAZEPAM (brand delisting)

Tab 10 mg	6.17	100	Ox-Pam
Tab 15 mg	8.53	100	Ox-Pam

Note – Ox-Pam tab 10 mg and 15 mg brand to be delisted 1 April 2022.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 February 2022 (continued)

133 NICOTINE (amended restriction criteria)

➔ Oral spray 1 mg per dose — *e.g. Nicorette QuickMist Mouth Spray*

➔ Soln for inhalation 15 mg cartridge — *e.g. Nicorette Inhalator*

Restricted
Initiation
Any of the following:
1 For perioperative use in patients who have a 'nil by mouth' instruction; or
2 For use within mental health inpatient units; or
3 Patient would be admitted to a mental health inpatient unit, but is unable to due to COVID-19 self-isolation requirement; or
~~3~~**4** For acute use in agitated patients who are unable to leave the hospital facilities.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

138 BORTEZOMIB (presentation delisting)

➔ Inj 2.5 mg vial

Note – Bortezomib inj 2.5 mg vial presentation to be delisted 1 August 2022.

149 SUNITINIB (brand change and addition of PSS)

➔ Cap 12.5 mg – **5% DV Jul-22 to 2024**	208.38	28	**Sunitinib Pfizer**
➔ Cap 25 mg – **5% DV Jul-22 to 2024**	416.77	28	**Sunitinib Pfizer**
➔ Cap 50 mg – **5% DV Jul-22 to 2024**	694.62	28	**Sunitinib Pfizer**

Note – Sutent cap 12.5 mg, 25 mg and 50 mg to be delisted 1 July 2022.

152 MEGESTROL ACETATE – Restricted: For continuation only (new listing)

➔ Tab 160 mg	48.80	30	Megace

Note – Megace tab 16 mg to be delisted 1 February 2023.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 February 2022 (continued)

174 CASIRIVIMAB AND IMDEVIMAB (new listing)

➔ Inj 120 mg per ml casirivimab, 11.1 ml vial (1) and
inj 120 mg per ml imdevimab, 11.1 ml vial (1)..... 0.00 1 Ronapreve

Restricted
Initiation – mild to moderate COVID-19-hospitalised patients
Limited to 2 weeks
All of the following:
1 Patient has confirmed (or probable) COVID-19; and
2 Patient is an in-patient in hospital with mild to moderate disease severity*; and
3 Patient's symptoms started within the last 10 days; and
4 Patient is not receiving high flow oxygen or assisted/mechanical ventilation; and
5 Any of the following:
  5.1 Age > 50; or
  5.2 BMI >30; or
  5.3 Patient is Māori or Pacific ethnicity; or
  5.4 Patient is at increased risk of severe illness from COVID-19, excluding pregnancy, as described on the Ministry of Health website (see Notes); and
6 Either:
  6.1 Patient is unvaccinated; or
  6.2 Patient is seronegative where serology testing is readily available or strongly suspected to be seronegative where serology testing is not readily available; and
7 Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg.

Note:* Mild to moderate disease severity as described on the Ministry of Health Website
** (https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-information-specific-audiences/covid-19-advice-higher-risk-people)

Initiation – Treatment of profoundly immunocompromised patients
Limited to 2 weeks
All of the following:
1 Patient has confirmed (or probable) COVID-19; and
2 The patient is in the community (treated as an outpatient) with mild to moderate disease severity*; and
3 Patient is profoundly immunocompromised** and is at risk of not having mounted an adequate response to vaccination against COVID-19 or is unvaccinated; and
4 Patient's symptoms started within the last 10 days; and
5 Patient is not receiving high flow oxygen or assisted/mechanical ventilation; and
6 Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg.

Note:* Mild to moderate disease severity as described on the Ministry of Health Website
** Examples include B-cell depletive illnesses or patients receiving treatment that is B-Cell depleting.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 February 2022 (continued)

200 TOCILIZUMAB (amended restriction criteria – affected criteria shown only)

➔ Inj 20 mg per ml, 4 ml vial	220.00	1	Actemra
➔ Inj 20 mg per ml, 10 ml vial	550.00	1	Actemra
➔ Inj 20 mg per ml, 20 ml vial	1,100.00	1	Actemra

Restricted
Indication – moderate to severe COVID-19*
Therapy limited to 1 dose
All of the following:
1 Patient has confirmed (or probable) COVID-19; and
2 Oxygen saturation of <92% on room air, or requiring supplemental oxygen; and
~~3 Patient has significantly increased laboratory markers of systemic inflammation (eg CRP, PCT or ferritin); and~~
3~~4~~ Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
4~~5~~ Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose**; and**
5 Tocilizumab is not to be administered in combination with barcitinib.
Note: Indications marked with * are unapproved indications.

211 BARICITINIB (new listing)

➔ Tab 2 mg	0.00	28	Olumiant
➔ Tab 4 mg	0.00	28	Olumiant

Restricted
Initiation – moderate to severe COVID-19*
Limited to 14 days treatment
All of the following:
1 Patient has confirmed (or probable) COVID-19*; and
2 Oxygen saturation of <92% on room air, or requiring supplemental oxygen; and
3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
4 Baricitinib is to be administered at doses no greater than 4 mg daily for up to 14 days; and
5 Baricitinib is not to be administered in combination with tocilizumab.

Note: Indications marked with * are unapproved indications.

SPECIAL FOODS

251 PAEDIATRIC ORAL FEED 1 KCAL/ML (presentation description change)

➔ Liquid ~~4.2~~**2.8** g protein, ~~16.7~~**11.2** g carbohydrate and ~~7.5~~**5** g fat per 100 ml, bottle	1.07	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)
➔ Liquid ~~4.2~~**2.8** g protein, ~~16.7~~**11.2** g carbohydrate and ~~7.5~~**5** g fat per 100 ml, can	1.34	250 ml	Pediasure (Vanilla)

251 PAEDIATRIC ORAL FEED 1.5 KCAL/ML (new listing)

➔ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle			*e.g. Pediasure Plus*

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Index

Pharmaceuticals and brands

New Zealand
Permit No. 478

Permit

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print)
ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand